CD20 positive

The six-year follow-up showed that concurrent and independent orbital MALT lymphoma and axillary reactive lymphoid hyperplasia, likely due to unicentric Castleman disease, were both stable. The present case illustrates how important it is to make pathological diagnoses in different anatomical lesions after the initial diagnosis of Castleman disease.

P1/2, N=38, Completed, Prof. Dr. Clemens Schmitt | Active, not recruiting --> Completed | Trial primary completion date: Jun 2024 --> Nov 2024

P1/2, N=543, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P=N/A, N=82, Completed, Eric Turcotte | Unknown status --> Completed

Seven months later, the patient underwent follow-up EGD, and the disappearance of lymphoma cells was confirmed histopathologically by biopsy. Repeated and detailed endoscopic examination should be considered in an immunosuppressed patient with treatment-resistant gastric or duodenal ulcers.

P3, N=423, Active, not recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Mar 2025 --> Jun 2025

Together these findings are consistent with a diagnosis of naturally occurring NK-cell lymphoproliferative disorder. NK-cell lymphoproliferative disorder has not been reported previously in rhesus macaques, to our knowledge.

P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: May 2026 --> Feb 2027

Gallbladder follicular lymphoma is difficult to diagnose preoperatively, however, extra-regional lymph node swelling and relatively low apparent diffusion coefficients on magnetic resonance imaging can help its diagnosis.

Cryoablation has shown good anti-tumor efficacy across various tumor types, including those affecting the bone. However, local control was inadequate for recurrent lesions and tumors larger than 4.0 cm in diameter. Further analysis of the relationship between macrophages and cryoablation is needed and may provide critical insights into achieving a more effective anti-tumor response.

The utilization of various B-cell markers in combination could aid pathologists in distinguishing between various stages of B-cell maturation, assessing tumor cell heterogeneity, and determining the phenotype in scenarios where there is a loss of common B-cell markers diffuse large B-cell lymphomas is the most prevalent subtype of feline lymphoma. Significantly, relying solely on immunochemistry with one parameter may not be sufficient for a definitive diagnosis of B-cell lymphoma, as another parameter may also be necessary.

The patient received eight cycles of the CHOP (doxorubicin, cyclophosphamide, prednisone, and vincristine) chemotherapy regimen, achieving complete clinical remission with no recurrence noted at the two-year follow-up. Early recognition is crucial for optimal treatment of this uncommon disease. Further research is needed to refine treatment protocols.

The patient subsequently received four cycles of chemotherapy using rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). After a follow-up of 17 months, the patient is alive with no evidence of disease. This report is being used to discuss the salient features of this rare entity and its differential diagnosis.

The immunohistochemical stains showed positive results for CD20, PAX5, BCL6, CD10, and high ki-67. The fluorescence in situ hybridization (FISH) test revealed a positive result for c-MYC gene rearrangement, but there was no evidence of the typical translocation associated with Burkitt lymphoma involving the IgH, kappa, or lambda genes.

DLBCL arising from the skull base often originates from the clivus and results in CN VI palsy. Current publications indicate a unique clinical presentation and immunohistochemical profile. Treatment generally involves biopsy, followed by chemo- and/or radiotherapy.

With prompt diagnosis, intervention and intensive monitoring, the end-organ damage was successfully prevented. This case report highlights the importance of keeping high index of suspicion for STLS even without a background history of malignancy as this life-threatening condition is potentially salvageable.

P1/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Phase classification: P1b/2 --> P1/2 | Trial primary completion date: May 2024 --> Jan 2024

P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Mar 2024 --> Mar 2025

P1, N=13, Recruiting, Wuhan Union Hospital, China

MTX-LPD can occur in the liver. Clinician should suspect hepatic MTX-LPD when a liver mass is detected in patient who had been treating with MTX for RA.

Complete remission was achieved with a reduced immunomodulatory drug dosage and rituximab therapy. She has been alive for 8 months postoperatively without recurrence. This case suggests that PTLD should be considered in assessing patients presenting with abdominal symptoms following organ transplantation.

In addition, longitudinal 18F-fluorodeoxyglucose positron-emission tomography (18F-FDG PET) of one MCM successfully detected lymphoproliferative disease in the adrenal glands prior to clinical signs of disease. These data demonstrate successful induction of lymphocryptovirus-associated PTLD-like disease in 4 of 5 MCMs, and thus support the use of MCMs as a preclinical NHP model of EBV-associated lymphoproliferative disease that could be employed to test novel diagnostic and therapeutic modalities.

These results demonstrate that CD3/CD20 positive lymphocytes can be accurately detected and characterized on H&E by deep learning and generalized across species. Collectively, these data suggest that our understanding of complex biological systems may benefit from computationally-derived spatial analysis, as well as integration of computational science and basic science.

P1, N=24, Suspended, Medical College of Wisconsin | Recruiting --> Suspended

P2, N=18, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025

P1/2, N=112, Recruiting, Shanghai AbelZeta Ltd. | Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025

Four months later, his ICH skin eruptions, eczematous plaques, and lymphoadenopathy gradually regressed. Our case supports the notion that the detection of ETV3-NCOA2 translocation can be useful for diagnosis of ICH.

P=N/A, N=28, Recruiting, University of California, San Francisco

P2, N=82, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial completion date: Feb 2028 --> Apr 2030

Zuberitamab (375 mg/m2) plus CHOP was non-inferior to R-CHOP regarding ORR but exhibited a higher CR rate and was well tolerated in CD20-positive, previously untreated Chinese patients with DLBCL.

A 75-year-old man presented with uveitis masquerade syndrome while undergoing treatment for MCL with rituximab-bendamustine. During the study course, CD5 and CD20 positive cells were identified in the anterior chamber of the eyes via flow cytometry, which was consistent with the pathological findings of biopsies. Ibrutinib may improve recurrent MCL intraocular lesions.

The combination of anlotinib and TQB2450 is effective and tolerable in ASPS patients. TLS may serve as a prognostic biomarker, meriting further investigation.

P=N/A, N=540, Active, not recruiting, International Extranodal Lymphoma Study Group (IELSG) | Phase classification: P3 --> P=N/A

P2, N=42, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2024

Herein, we report about an 85-year-old Japanese woman who was diagnosed with SLE 26 years ago and was stable and maintained on prednisone (5 mg/day) for 20 years...Treatment with tirabrutinib (480 mg once daily) was started. The patient achieved clinical response to treatment, as evidenced by improved mental status. In patients with SLE who present with multiple nodular or ring-like lesions on brain MRI, brain biopsy with histological diagnosis is crucial for the exclusion of CNS-LYG.

P3, N=1000, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026

Treatment with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone has become the standard of care for newly diagnosed CD20-positive DLBCL with an International Prognostic Index score of 2 to 5, based on its reported efficacy for this indication. In addition, the development of immunotherapy such as anti-CD19-chimeric antigen receptor (CAR)-T therapy and bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab has led to a paradigm shift in treatment of relapsed/refractory DLBCL. This review summarizes the evolution of treatment development for DLBCL, as well as the results of the current clinical standard of care and new therapies that are expected to become the standard of care.

However, it is also expressed in other types of DLBCLs, making it less specific. Most CNS-DLBCL cases can be diagnosed without performing IHC for IMP3 expression, but it may be a useful adjunctive tool to differentiate from reactive lesions when tumor cells are few or deformed.

Here, we describe the unique case of a 50-year-old self-experimenting female virologist with locally recurrent muscle-invasive breast cancer who was able to proceed to simple, non-invasive tumour resection after receiving multiple intratumoural injections of research-grade virus preparations, which first included an Edmonston-Zagreb measles vaccine strain (MeV) and then a vesicular stomatitis virus Indiana strain (VSV), both prepared in her own laboratory. The patient completed one-year trastuzumab adjuvant therapy and remains well and recurrence-free 45 months post-surgery. Although an isolated case, it encourages consideration of oncolytic virotherapy as a neoadjuvant treatment modality.

Additionally, CB modulated peroxisome proliferator‑activated receptor γ (PPARγ) and MARCO expression in M2 macrophages and epithelial‑mesenchymal transition in A549 cells, which was partially reversed by rosiglitazone, a PPARγ agonist. Finally, CB and cisplatin treatments hindered tumor growth in vivo, with distinct impacts on animal body weight and macrophage marker expression in tumor tissues. In conclusion, the results of the present study demonstrated that CB exerted complex regulatory effects on macrophage polarization and tumor progression, suggesting its potential as a modulator of the tumor microenvironment and a therapeutic for cancer treatment.

Further investigation and documentation of similar cases is imperative to elucidate the clinical features, prognosis, and optimal therapeutic strategies. The long-term prognosis and outcomes in patients with hypopigmented MF and CD20 positivity remain ambiguous, underscoring the necessity for continued research and scrutiny of analogous cases.

DLBCL, while common among NHLs, rarely presents as primary extranodal lymphoma in skeletal muscle. The presented case underscores the importance of considering DLBCL in differential diagnoses for atypical soft tissue masses and the effectiveness of R-CHOP chemotherapy in managing this rare presentation. Prompt and appropriate treatment, such as R-CHOP chemotherapy, is essential for favorable outcomes.